<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">25897409</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2193-1801</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>SpringerPlus</Title>
                <ISOAbbreviation>Springerplus</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>152</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40064-015-0929-3</ELocationID>
            <Abstract>
                <AbstractText>Platinum-based chemoradiotherapy (CRT) is a standard front-line treatment for locally advanced non-small cell lung cancer (NSCLC). However, no clinical trials have compared the efficacy and toxicity of platinum combination and docetaxel as subsequent re-challenge chemotherapies after cancer recurrence following CRT. This study aimed to evaluate the efficacy and toxicity of platinum combination chemotherapy versus docetaxel monotherapy in NSCLC patients previously treated with platinum-based CRT. From September 2002 to December 2009, at three participating institutions, 24 patients with locally advanced NSCLC, who had previously received platinum-based CRT, were treated with platinum combination re-challenge therapy, whereas 61 received docetaxel monotherapy. We reviewed their medical charts to evaluate patient characteristics and data regarding treatment response, survival, and toxicity. The response rates were 16.7% and 6.6% in the platinum combination chemotherapy and docetaxel monotherapy groups, respectively (p = 0.09), whereas disease control rates were 58.3% and 57.4%, respectively (p = 0.82). Progression-free survival was similar between the two groups (median, 4.2 vs. 2.3 months; hazard ratio [HR] = 0.81; 95% confidence interval [CI] = 0.51-1.29; p = 0.38), as was overall survival (median, 16.5 vs. 13.0 months; HR = 0.82; 95% CI = 0.47-1.41; p = 0.47). The incidence and severity of toxicity was also similar between the two groups. Hematological toxicity, particularly leukopenia and neutropenia, was more frequent in the docetaxel group. Our results indicated that platinum combination re-challenge was equivalent to docetaxel for relapsed patients previously treated with platinum-based CRT. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Imai</LastName>
                    <ForeName>Hisao</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan ; Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaira</LastName>
                    <ForeName>Kyoichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan ; Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mori</LastName>
                    <ForeName>Keita</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Trial Coordination Office, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ono</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akamatsu</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taira</LastName>
                    <ForeName>Tetsuhiko</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshino</LastName>
                    <ForeName>Reiko</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kenmotsu</LastName>
                    <ForeName>Hirotsugu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saitoh</LastName>
                    <ForeName>Jun-Ichi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harada</LastName>
                    <ForeName>Hideyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naito</LastName>
                    <ForeName>Tateaki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murakami</LastName>
                    <ForeName>Haruyasu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomizawa</LastName>
                    <ForeName>Yoshio</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuura</LastName>
                    <ForeName>Masana</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saito</LastName>
                    <ForeName>Ryusei</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakajima</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Diagnostic Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamada</LastName>
                    <ForeName>Masanobu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Toshiaki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Suntou-gun Shizuoka, 411-8777 Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Springerplus</MedlineTA>
            <NlmUniqueID>101597967</NlmUniqueID>
            <ISSNLinking>2193-1801</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Chemoradiotherapy</Keyword>
            <Keyword MajorTopicYN="N">Docetaxel</Keyword>
            <Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
            <Keyword MajorTopicYN="N">Platinum combination</Keyword>
            <Keyword MajorTopicYN="N">Recurrence</Keyword>
            <Keyword MajorTopicYN="N">Second-line chemotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25897409</ArticleId>
            <ArticleId IdType="doi">10.1186/s40064-015-0929-3</ArticleId>
            <ArticleId IdType="pii">929</ArticleId>
            <ArticleId IdType="pmc">PMC4395619</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10655437</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 May 1;25(13):1698-704</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17404369</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 2012 May;138(5):745-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22258853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Jpn J Clin Oncol. 1997 Jun;27(3):166-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9255271</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2004 May 1;22(9):1589-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15117980</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 May;18(10):2095-103</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10811675</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lung Cancer. 2010 Sep;69(3):315-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20071052</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Oct 1;27(28):4649-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19720909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Dec 20;30(36):4501-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23109689</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 Jun;18(12):2354-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10856094</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2006 Mar;17(3):473-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16500915</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chest. 2000 Feb;117(2):358-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10669675</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2015 Mar;65(2):87-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25651787</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chemotherapy. 2013;59(4):307-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24480845</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22237781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2002 Oct 7;87(8):825-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12373594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2012 Jan;69(1):99-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21607554</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Lung Cancer. 2013 Sep;14(5):508-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23792009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jul 10;28(20):3299-306</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20530281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 May 1;28(13):2181-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20351327</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Oct 1;29(28):3825-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21900105</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lung Cancer. 2010 May;68(2):269-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19660826</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 Nov 1;18(21):3722-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11054445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 May 1;23(13):2926-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15728229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25115305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Jun 20;24(18):2800-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16682727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Oncol. 2006 Jun;11(3):190-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16850125</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2004 Jan;15(1):173-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14679138</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Aug 10;28(23 ):3739-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20625120</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Dec 10;26(35):5755-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19001323</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>